Sourcing Success in Cell and Gene Therapy Development
As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success.
As cell and gene therapies are garnering more interest within the biopharma industry, demand for adequate manufacturing capacity and talent to ensure success is increasing. To explore how outsourcing can prove beneficial for cell and gene therapy (CGT) development, BioPharm International spoke with Miguel Forte, chief commercialization officer, ISCT, CEO of Bone Therapeutics, and former CEO of Zelluna Immunotherapy; Alengo Nyamay’antu, scientific communications manager, Polyplus-transfection; and Matthew Lakelin, vice-president business development and scientific affairs, TrakCel.
Read this article in BioPharm International’s Outsourcing Resources February 2020 eBook.
About the Author
Felicity Thomas is the European editor for BioPharm International.
Article Details
BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Pages: 8–11
Citation
When referring to this article, please cite it as F. Thomas, “Sourcing Success in Cell and Gene Therapy Development," BioPharm International Outsourcing Resources eBook (February 2020).
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
